BMY watch $46.xx: Double Golden zone that could mark the BottomBMY has been dropping along with pharma sector.
Bulls regained Double Golden zone but not safe yet.
Looking for a Break-and-Retest to mark the bottom.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.364 CHF
−8.13 B CHF
43.87 B CHF
2.03 B
About Bristol-Myers Squibb Company
Sector
Industry
CEO
Christopher S. Boerner
Website
Headquarters
Princeton
Founded
1933
FIGI
BBG006TLNGL4
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
$BMYLooks like price is near a support range dating back between November and February of 2024. If you look at the "throw up" emoji, there was a nice flat down drop in price and since then, it seems like we are at the brink of possibly starting to gas out a bit for some potential relief. They just came
BMY watch $61: Key Support to launch next leg up into $64BMY at a key support zone of fib cluster at $60.90-60.98.
Next leg may be a choppy rise to resistance at $63.86-64.56.
Break of support would of course negate the planned longs.
=====================================================
.
Bristol will fall an extra 10%NYSE:BMY has reported somewhat disappointing results for 2025, and the investors' disappointment is evident in the breakdown of the double top that had formed.
This suggests a likely drop of about 10% in the stock price, although it doesn't affect the long term. The weaker sales in generic dr
BMY: Technical and Fundamental AnalysisBMY: Technical and Fundamental Analysis
Two recent developments initiated a bearish movement in BMY last week:
News_1: Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial
Bristol-Myers Squibb said its Phase 3 trial evaluating opdualag for the adjuv
Speculative Madness: The Market’s Bubble Stocks Some stocks areSpeculative Madness: The Market’s Bubble Stocks
Some stocks aren't just overvalued—they're in full speculative bubble mode. Fundamentals? Irrelevant. When euphoria takes over, rationality disappears.
Here’s my list of bubble stocks that scream unsustainable pricing:
SBUX, T, PLTR, BMY, PYPL, NFLX
Bristol-Myers Squibb (BMY): A Strong Player in BiopharmaBristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader focused on developing innovative medicines to address serious diseases. The company specializes in treatments for cancer, cardiovascular conditions, and immune disorders. With a portfolio that includes well-known drugs like Opdi
$BMY #BMY happens to be my better July was slow as in hell , but I stick with trading NYSE:BMY for the whole month , #WEBBY's #RSI was a big help to check on funds liquidity infusion , trim from dividend's collected from #oilandgas
Freedom was in trade and secured by capital available 2x and second 3x $ i.e. 1/2 and 3/4 on each
Bullish rebound in place, and possibly a strong oneNYSE:BMY is looking at a possible rebound going forward, especially after a strong gap up. Despite pre market is lower, as long as the selling pressure is not strong for the next 3-4 periods, it is a long-term buy
BMY Swing TradeBristol-Myers Squibb Co (BMY)
BMY has been on a downtrend since December 2022 but since its recent Dividend payout followed by good earnings, it seems like a reversal of trend is in the making.
Following a month-long consolidation period, a bullish candlestick formation at today's close could indi
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042Yield to maturity
6.70%
Maturity date
Aug 1, 2042
BMY5009254
Bristol-Myers Squibb Company 4.25% 26-OCT-2049Yield to maturity
6.60%
Maturity date
Oct 26, 2049
BMY5009253
Bristol-Myers Squibb Company 4.625% 15-MAY-2044Yield to maturity
6.48%
Maturity date
May 15, 2044
See all BRM bonds
Curated watchlists where BRM is featured.
Related stocks
Frequently Asked Questions
The current price of BRM is 38.976 CHF — it has decreased by −25.18% in the past 24 hours. Watch BRISTOL-MYRS SQUIB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BRISTOL-MYRS SQUIB stocks are traded under the ticker BRM.
BRM stock has fallen by −25.18% compared to the previous week, the month change is a −25.18% fall, over the last year BRISTOL-MYRS SQUIB has showed a 2.67% increase.
We've gathered analysts' opinions on BRISTOL-MYRS SQUIB future price: according to them, BRM price has a max estimate of 55.86 CHF and a min estimate of 29.57 CHF. Watch BRM chart and read a more detailed BRISTOL-MYRS SQUIB stock forecast: see what analysts think of BRISTOL-MYRS SQUIB and suggest that you do with its stocks.
BRM stock is 33.66% volatile and has beta coefficient of 0.13. Track BRISTOL-MYRS SQUIB stock price on the chart and check out the list of the most volatile stocks — is BRISTOL-MYRS SQUIB there?
Today BRISTOL-MYRS SQUIB has the market capitalization of 79.13 B, it has decreased by −2.60% over the last week.
Yes, you can track BRISTOL-MYRS SQUIB financials in yearly and quarterly reports right on TradingView.
BRISTOL-MYRS SQUIB is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
BRM earnings for the last quarter are 1.59 CHF per share, whereas the estimation was 1.32 CHF resulting in a 20.43% surprise. The estimated earnings for the next quarter are 1.39 CHF per share. See more details about BRISTOL-MYRS SQUIB earnings.
BRISTOL-MYRS SQUIB revenue for the last quarter amounts to 9.92 B CHF, despite the estimated figure of 9.47 B CHF. In the next quarter, revenue is expected to reach 9.35 B CHF.
BRM net income for the last quarter is 2.17 B CHF, while the quarter before that showed 65.39 M CHF of net income which accounts for 3.22 K% change. Track more BRISTOL-MYRS SQUIB financial stats to get the full picture.
Yes, BRM dividends are paid quarterly. The last dividend per share was 0.53 CHF. As of today, Dividend Yield (TTM)% is 5.19%. Tracking BRISTOL-MYRS SQUIB dividends might help you take more informed decisions.
As of May 29, 2025, the company has 34.1 K employees. See our rating of the largest employees — is BRISTOL-MYRS SQUIB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRISTOL-MYRS SQUIB EBITDA is 16.77 B CHF, and current EBITDA margin is 39.98%. See more stats in BRISTOL-MYRS SQUIB financial statements.
Like other stocks, BRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRISTOL-MYRS SQUIB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BRISTOL-MYRS SQUIB technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BRISTOL-MYRS SQUIB stock shows the strong sell signal. See more of BRISTOL-MYRS SQUIB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.